Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Is DOGE a cybersecurity crisis? Musk inserts himself into OpenAI’s transition, Vance wants less international tech regulation ...

In recent years, Large Language Models (LLMs) have significantly redefined the field of artificial intelligence (AI), ...

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.

When the director of a small regional science nonprofit sat down last week to pay a few bills, she got a shock. In the fall, ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Key Takeaways Outpace competitors by using data science to make smarter decisions and better serve your customers. Start ...

On Tuesday, software company Inuvo launched IntentKey, an audience insights platform that creates real-time models for targeting ads.

The way we seek and process information has experienced a significant transformation over the past few years. Advances in ...

The Commerce Department has sent NOAA officials a broad set of keywords to search grants in ways that would cover most ...